Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
The ongoing sunRIZE extension includes treatment lasting approximately nine months to well over two years, with continued glycemic control.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rezolute (RZLT) announced that FDA recommended a pre-BLA meeting before a potential biologics license application for ersodetug in congenital hyperinsulinism.
Following preliminary review of Phase 3 sunRIZE data, FDA encouraged the next regulatory step despite missed primary and key secondary endpoints. Reductions in low-blood-sugar events measured by finger-stick testing were not statistically significant versus placebo. The continuous glucose monitoring endpoint also missed its Week 24 target, although improvements appeared across multiple monitoring-based endpoints in both treatment arms. FDA did not assess approvability; that determination requires formal application review.
Rezolute expects Phase 3 upLIFT results in tumor-related hyperinsulinism this quarter and will then evaluate its submission strategy for potentially both programs. A tumor-related pre-BLA meeting depends on results supporting a submission.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointFDA recommended a pre-BLA meeting for congenital hyperinsulinism after preliminary review of detailed sunRIZE data.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Rezolute remains on track for Phase 3 upLIFT topline results this quarter in tumor-related hyperinsulinism.
- Minor pointCGM-based hypoglycemia endpoints showed consistent improvements described as clinically relevant in both treatment arms.
- Minor pointOngoing sunRIZE extension has high retention, with treatment lasting approximately nine months to well over two years.
- Minor pointExtension observations include continued glycemic control and reduced use of background standard-of-care therapies.
Negative
- Major pointsunRIZE primary endpoint missed: finger-stick hypoglycemia-event reductions were not statistically significant versus placebo.
- Moderate pointKey secondary endpoint missed: continuous-monitoring time in hypoglycemia at the Week 24 End-of-Treatment evaluable window.
- Minor pointFDA did not opine on approvability; a determination requires in-depth evaluation during formal BLA review.
- Minor point. Forward-looking: it has not happened yet and may not happen.Tumor-related pre-BLA meeting remains conditional on upLIFT results supporting a submission.
Details
Market move: RZLT +4.74% vs previous close. pre-BLA meeting recommendation
On Oct 5, the day this news came out, the latest delayed price for RZLT is 4.74% above the previous close. Argus tracked a peak move of +9.0% during the session. Our momentum scanner has recorded 3 alerts for this stock so far that day. The latest delayed price is $4.20. Relative volume is elevated at 2.1x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- upLIFT topline results
- this quarter
- Tumor HI study; results expected
Historical Context
-
sunRIZE missed its primary endpoint, with data still under FDA review.
-
FDA continued reviewing sunRIZE data after endpoint misses and requested submitted datasets.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
biologics license application (bla) regulatory
continuous glucose monitoring (cgm) medical
self-monitored blood glucose (smbg) medical
open-label extension (ole) medical
monoclonal antibody medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these patient communities
On track to report topline results for the Phase 3 upLIFT study in tumor HI this quarter
REDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (“HI”), today announced that following a preliminary review of detailed data from the Phase 3 sunRIZE study of ersodetug for the treatment of hypoglycemia due to congenital HI, the U.S. Food and Drug Administration (“FDA” or “Agency”) recommended a pre-BLA meeting with the Company as a precursor to submitting a BLA.
As previously reported, sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI, demonstrated glycemic improvements, but did not meet the primary endpoint because the reductions in hypoglycemia events by finger-stick self-monitored blood glucose (SMBG) were not statistically significant compared to placebo. Although the key secondary endpoint of time in hypoglycemia by continuous glucose monitoring (CGM) was not met in the Week 24 End-of-Treatment evaluable window, consistent and clinically relevant improvements in hypoglycemia were observed for this and multiple other CGM-based hypoglycemia endpoints in both treatment arms.
At a March 2026 Type B meeting with FDA, the Agency acknowledged the challenges posed by behavioral factors in clinical trials in this patient population, including limitations associated with SMBG based measures of hypoglycemia. At the meeting, the Agency requested that the Company provide the continuous CGM data for its independent review. In June 2026, the Company submitted source and analysis datasets, and summary results from a substantial number of pre-specified, post-hoc, and sensitivity analyses.
The Agency has reviewed the data and, despite the trial’s failure to meet the prespecified primary and key secondary endpoints, as a next step, encouraged the Company to request a Type B pre-BLA meeting as a precursor to submitting a BLA for congenital HI. The Agency explicitly did not opine on the approvability of ersodetug for congenital HI and noted that any such determination would only be made as a part of an in-depth evaluation of the supporting data during a formal BLA review, as is customary during a BLA process.
In light of expected topline results this quarter from the Company’s upLIFT study in tumor HI and the potential for an additional pre-BLA meeting for that indication should the study results support a submission, the Company will evaluate its overall BLA submission strategy for potentially both programs following the announcement of upLIFT study results.
“We appreciate FDA’s thorough review of the extensive body of data generated in sunRIZE and are encouraged by the Agency’s recognition that this data will require in-depth evaluation during a formal BLA review,” said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. “We share FDA’s commitment to addressing the significant unmet needs of individuals living with rare diseases like congenital HI, where traditional drug development can present unique challenges. We believe this unusual process of preliminary review of detailed data demonstrates what can be achieved when regulators, companies, clinicians, and advocacy organizations work collaboratively to evaluate the totality of evidence for promising rare disease therapies.”
“For many people living with congenital hyperinsulinism, the threat of severe and unpredictable hypoglycemia remains a daily reality, and existing treatments are not enough,” said Julie Raskin, Chief Executive Officer of Congenital Hyperinsulinism International (CHI). “We are encouraged by the progress toward potential new therapies and grateful to the patients, families, researchers, clinicians, regulators, and biotechnology companies working together to bring better options to our community.”
The open-label extension (OLE) phase of the study is ongoing, with a continued high retention rate, equating to an ersodetug treatment duration in sunRIZE ranging from approximately nine months to well over two years. This, along with continued glycemic control and a notable reduction in the use of background standard of care therapies, potentially indicate continued glycemic and clinical benefit with ersodetug in longer-term use.
About Ersodetug
Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from pancreatic insulin or paraneoplastic IGF-2 secretion and from entero-incretin pathways, it has the potential to be universally effective at treating refractory hypoglycemia due to any form of hyperinsulinism (HI), including congenital HI, tumor HI (insulinoma, non-islet cell tumors) or bariatric/non-bariatric gastrointestinal surgery hypoglycemia. Ersodetug for the treatment of HI is investigational. Statements about safety and efficacy have not been approved by any health authority.
About Rezolute, Inc.
Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com.
Forward-Looking Statements
This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. These forward-looking statements include, but are not limited to, the overall BLA process, the potential efficacy of ersodetug in treating hypoglycemia as well as our ability to complete enrollment of the upLIFT study this year and announce topline results. Our ability to predict results or our plans or strategies is inherently uncertain. Notably, despite the FDA encouraging us to request a pre-BLA meeting for congenital HI, there can be no assurance that FDA will agree with the Company that the totality of evidence from the sunRIZE program demonstrates a clinically meaningful benefit or is sufficient to support the approval for ersodetug in congenital HI. Accordingly, FDA may determine that additional clinical data, including data from a new randomized controlled trial similar to sunRIZE, are required to support approval. Should the Agency make such a determination, it would adversely impact the timing and feasibility of approval for the congenital HI indication as well as the the commercial potential for ersodetug. Actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.
Contacts:
Christen Baglaneas
Rezolute, Inc.
1411 Broadway, 16th Floor
New York, NY 10018
cbaglaneas@rezolutebio.com
508-272-6717
Carrie McKim
Rezolute, Inc.
1411 Broadway, 16th Floor
New York, NY 10018
cmkim@rezolutebio.com
336-608-9706
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did FDA recommend for Rezolute's ersodetug application in congenital hyperinsulinism?
FDA recommended that Rezolute request a Type B pre-BLA meeting before submitting a biologics license application for congenital hyperinsulinism. This followed preliminary review of detailed sunRIZE data. FDA did not express a view on approvability, which would be determined during formal application review.
Why did FDA request additional sunRIZE continuous glucose monitoring data from Rezolute?
At a March 2026 Type B meeting, FDA acknowledged behavioral challenges in trials involving this patient population, including limitations of finger-stick blood glucose measures, and requested continuous glucose monitoring data for independent review. Rezolute submitted source and analysis datasets in June 2026, alongside summaries of pre-specified, post-hoc and sensitivity analyses.
What has Rezolute reported from the sunRIZE open-label extension?
The ongoing open-label extension has high retention, continued glycemic control and reduced use of background standard-of-care therapies. Treatment duration ranges from approximately nine months to well over two years. Rezolute views these observations as potentially indicating continued glycemic and clinical benefit with longer-term ersodetug use.